Matching articles for "roflumilast"
Issue 1749 · March 2, 2026
Drugs for Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):33-40 doi:10.58347/tml.2026.1749a
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
Issue 1749 · March 2, 2026 Free
Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis (online only)

View the Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):e41-2 doi:10.58347/tml.2026.1749d
View the Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis
Issue 1723 · March 3, 2025
Tapinarof Cream (Vtama) for Atopic Dermatitis

Tapinarof 1% cream ( Vtama – Dermavant), an aryl hydrocarbon receptor (AhR) agonist, has been approved by the FDA for topical treatment of atopic dermatitis in patients ≥2 years old. Tapinarof is the first…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):37-8 doi:10.58347/tml.2025.1723c
Tapinarof 1% cream ( Vtama – Dermavant), an aryl hydrocarbon receptor (AhR) agonist, has been approved by the FDA for topical treatment of atopic dermatitis in patients ≥2 years old. Tapinarof is the first AhR agonist to be approved in the US for this indication. It was approved in 2022 for treatment of plaque psoriasis in adults.
Issue 1720 · January 20, 2025
Dupilumab (Dupixent) for COPD

The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab ( Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of adults with inadequately controlled…

Med Lett Drugs Ther. 2025 Jan 20; 67(1720):11-3 doi:10.58347/tml.2025.1720c
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab ( Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupilumab is the first biologic drug to be approved in the US for this indication. It has been available for years for treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis.
Issue 1712 · September 30, 2024
Drugs for Plaque Psoriasis

Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with…

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):153-60 doi:10.58347/tml.2024.1712a
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Issue 1712 · September 30, 2024
Comparison Table: Some Drugs for Plaque Psoriasis (online only)

View the Comparison Table: Some Drugs for Plaque Psoriasis

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):e160-6 doi:10.58347/tml.2024.1712b
View the Comparison Table: Some Drugs for Plaque Psoriasis
Issue 1711 · September 16, 2024
Roflumilast Cream (Zoryve) for Atopic Dermatitis

The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6…

Med Lett Drugs Ther. 2024 Sep 16; 66(1711):150-1 doi:10.58347/tml.2024.1711b
The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa) , which can be used in patients ≥3 months old, was the first. Roflumilast is available as Zoryve in a 0.3% cream for treatment of plaque psoriasis and a 0.3% foam for treatment of seborrheic dermatitis. It is also available in an oral formulation (Daliresp) for treatment of chronic obstructive pulmonary disease.
Issue 1710 · September 2, 2024
Drugs for COPD

The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD…

Med Lett Drugs Ther. 2024 Sep 2; 66(1710):137-44 doi:10.58347/tml.2024.1710a
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Issue 1709 · August 19, 2024
Ensifentrine (Ohtuvayre) for COPD

The FDA has approved ensifentrine ( Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):131-3 doi:10.58347/tml.2024.1709b
The FDA has approved ensifentrine ( Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the first dual inhibitor of PDE3 and PDE4 to be approved by the FDA, and the first inhaled drug with a new mechanism of action to be approved for treatment of COPD in more than 20 years.
Issue 1709 · August 19, 2024
Ryzneuta for Prevention of Febrile Neutropenia

Efbemalenograstim alfa-vuxw ( Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):134-5 doi:10.58347/tml.2024.1709d
Efbemalenograstim alfa-vuxw ( Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first nonpegylated, long-acting G-CSF to become available in the US. Two pegylated, long-acting G-CSFs, pegfilgrastim ( Neulasta , and biosimilars) and eflapegrastim (Rolvedon) , are also available.
Issue 1700 · April 15, 2024
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast…

Med Lett Drugs Ther. 2024 Apr 15; 66(1700):57-9 doi:10.58347/tml.2024.1700a
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication. It is also available in a 0.3% cream formulation (Zoryve) for treatment of plaque psoriasis and in an oral formulation ( Dalires p, and generics) for treatment of chronic obstructive pulmonary disease. A 0.15% cream formulation for treatment of atopic dermatitis in patients ≥6 years old will be reviewed by the FDA in July.
Issue 1668 · January 23, 2023
Topical Roflumilast (Zoryve) for Plaque Psoriasis

The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):10-2 doi:10.58347/tml.2023.1668b
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is the first topical PDE4 inhibitor to be approved by the FDA for this indication; crisaborole (Eucrisa) , another topical PDE4 inhibitor, is approved for treatment of atopic dermatitis. Oral roflumilast (Daliresp) is approved for treatment of chronic obstructive pulmonary disease.
Issue 1606 · September 7, 2020
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and…

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):137-44
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Issue 1518 · April 10, 2017
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for…

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):57-62
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Issue 1424 · September 2, 2013
Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD

The FDA has approved an inhaled fixed-dose combination ( Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta 2 -adrenergic agonist (LABA) vilanterol trifenatate…

Med Lett Drugs Ther. 2013 Sep 2; 55(1424):69-71
The FDA has approved an inhaled fixed-dose combination ( Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta 2 -adrenergic agonist (LABA) vilanterol trifenatate for once-daily treatment of chronic obstructive pulmonary disease (COPD).
Issue 132 · August 1, 2013
Drugs for Asthma and COPD

INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children…

Treat Guidel Med Lett. 2013 Aug; 11(132):75-86
INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children and the elderly, use MDIs effectively. VHCs have one-way valves that prevent the patient from exhaling into the device, minimizing the need for coordinated actuation and inhalation. Spacers are tubes or chambers placed between the canister and a face mask or mouthpiece, which also avoids the need to coordinate actuation and inhalation. Both VHCs and spacers retain the larger particles emitted from the MDI, decreasing their deposition in the oropharynx and leading to a higher proportion of small respirable particles being inhaled.
Issue 1369 · July 25, 2011
Roflumilast (Daliresp) for COPD

Roflumilast ( Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease…

Med Lett Drugs Ther. 2011 Jul 25; 53(1369):59-60
Roflumilast ( Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.